New hope for tough cancers: experimental drug CT3001 enters human trials
Disease control
Recruiting now
This early-stage study tests a new drug called CT3001 in people with advanced solid tumors (like colorectal or pancreatic cancer) that haven't responded to standard treatments. The study has two parts: first, finding a safe dose of CT3001 alone, then testing it combined with chem…
Phase: PHASE1, PHASE2 • Sponsor: Crossignal Therapeutics, Inc. • Aim: Disease control
Last updated May 20, 2026 11:54 UTC